Cargando…

The Diagnostic Utility of Anti-cyclic Citrullinated Peptide Antibodies, Matrix Metalloproteinase-3, Rheumatoid Factor, Erythrocyte Sedimentation Rate, and C-reactive Protein in Patients with Erosive and Non-erosive Rheumatoid Arthritis

Objective: To compare the diagnostic utility of laboratory variables, including matrix metalloproteinase-3 (MMP-3), anti-cyclic citrullinated peptide (CCP) antibodies, rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) in patients with erosive and non-erosive...

Descripción completa

Detalles Bibliográficos
Autores principales: Shovman, O., Gilburd, B., Zandman-Goddard, G., Sherer, Y., Orbach, H., Gerli, R., Shoenfeld, Y.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2005
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2275423/
https://www.ncbi.nlm.nih.gov/pubmed/16295525
http://dx.doi.org/10.1080/17402520500233510
_version_ 1782151869499441152
author Shovman, O.
Gilburd, B.
Zandman-Goddard, G.
Sherer, Y.
Orbach, H.
Gerli, R.
Shoenfeld, Y.
author_facet Shovman, O.
Gilburd, B.
Zandman-Goddard, G.
Sherer, Y.
Orbach, H.
Gerli, R.
Shoenfeld, Y.
author_sort Shovman, O.
collection PubMed
description Objective: To compare the diagnostic utility of laboratory variables, including matrix metalloproteinase-3 (MMP-3), anti-cyclic citrullinated peptide (CCP) antibodies, rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) in patients with erosive and non-erosive rheumatoid arthritis (RA). Methods: We assembled a training set, consisting of 60 patients with RA, all fulfilling the revised criteria of the American College of Rheumatology. A commercial enzyme linked immunosorbent assay (ELISA) was used both to test for anti-CCP antibodies (second generation ELISA kit) and MMP; RF were detected by latex-enhanced immunonephelometric assay. CRP was measured by latex turbidimetric immunoassay. Results: The levels of anti-CCP antibody titers and ESR were significantly higher in patients with erosive disease than those in non-erosive RA patients (p < 0.001 and 0.0341) respectively. Moreover, a higher frequency of elevated titers of anti-CCP antibodies was found in RA patients with erosions compared to patients with non-erosive RA (78.3% vs. 43.2% respectively). The ROC curves of anti-CCP passed closer to the upper left corner than those other markers and area under the curve (AUC) of anti-CCP was significantly larger than AUC of other markers (0.755 for anti-CCP, 0.660 for ESR, 0.611 for CRP, 0.577 for RF, and 0.484 for MMP-3 female). A positive predictive value was higher for anti-CCP antibodies in comparison to other markers. We did not find significant statistical correlation between anti-CCP antibody titers and inflammatory markers such as ESR or CRP. However, we confirmed the correlation of elevated titers of anti-CCP antibodies and RF in both groups of patients whereas the degree of correlation was more significant in non-erosive patients. Conclusion: The results of our study suggest that the presence of elevated anti-CCP antibody titers have better diagnostic performance than MMP-3, RF, CRP and ESR in patients with erosive RA.
format Text
id pubmed-2275423
institution National Center for Biotechnology Information
language English
publishDate 2005
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-22754232008-03-31 The Diagnostic Utility of Anti-cyclic Citrullinated Peptide Antibodies, Matrix Metalloproteinase-3, Rheumatoid Factor, Erythrocyte Sedimentation Rate, and C-reactive Protein in Patients with Erosive and Non-erosive Rheumatoid Arthritis Shovman, O. Gilburd, B. Zandman-Goddard, G. Sherer, Y. Orbach, H. Gerli, R. Shoenfeld, Y. Clin Dev Immunol Research Article Objective: To compare the diagnostic utility of laboratory variables, including matrix metalloproteinase-3 (MMP-3), anti-cyclic citrullinated peptide (CCP) antibodies, rheumatoid factor (RF), erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) in patients with erosive and non-erosive rheumatoid arthritis (RA). Methods: We assembled a training set, consisting of 60 patients with RA, all fulfilling the revised criteria of the American College of Rheumatology. A commercial enzyme linked immunosorbent assay (ELISA) was used both to test for anti-CCP antibodies (second generation ELISA kit) and MMP; RF were detected by latex-enhanced immunonephelometric assay. CRP was measured by latex turbidimetric immunoassay. Results: The levels of anti-CCP antibody titers and ESR were significantly higher in patients with erosive disease than those in non-erosive RA patients (p < 0.001 and 0.0341) respectively. Moreover, a higher frequency of elevated titers of anti-CCP antibodies was found in RA patients with erosions compared to patients with non-erosive RA (78.3% vs. 43.2% respectively). The ROC curves of anti-CCP passed closer to the upper left corner than those other markers and area under the curve (AUC) of anti-CCP was significantly larger than AUC of other markers (0.755 for anti-CCP, 0.660 for ESR, 0.611 for CRP, 0.577 for RF, and 0.484 for MMP-3 female). A positive predictive value was higher for anti-CCP antibodies in comparison to other markers. We did not find significant statistical correlation between anti-CCP antibody titers and inflammatory markers such as ESR or CRP. However, we confirmed the correlation of elevated titers of anti-CCP antibodies and RF in both groups of patients whereas the degree of correlation was more significant in non-erosive patients. Conclusion: The results of our study suggest that the presence of elevated anti-CCP antibody titers have better diagnostic performance than MMP-3, RF, CRP and ESR in patients with erosive RA. Hindawi Publishing Corporation 2005-09 /pmc/articles/PMC2275423/ /pubmed/16295525 http://dx.doi.org/10.1080/17402520500233510 Text en Copyright © 2005 Hindawi Publishing Corporation. http://creativecommons.org/licenses/by/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Shovman, O.
Gilburd, B.
Zandman-Goddard, G.
Sherer, Y.
Orbach, H.
Gerli, R.
Shoenfeld, Y.
The Diagnostic Utility of Anti-cyclic Citrullinated Peptide Antibodies, Matrix Metalloproteinase-3, Rheumatoid Factor, Erythrocyte Sedimentation Rate, and C-reactive Protein in Patients with Erosive and Non-erosive Rheumatoid Arthritis
title The Diagnostic Utility of Anti-cyclic Citrullinated Peptide Antibodies, Matrix Metalloproteinase-3, Rheumatoid Factor, Erythrocyte Sedimentation Rate, and C-reactive Protein in Patients with Erosive and Non-erosive Rheumatoid Arthritis
title_full The Diagnostic Utility of Anti-cyclic Citrullinated Peptide Antibodies, Matrix Metalloproteinase-3, Rheumatoid Factor, Erythrocyte Sedimentation Rate, and C-reactive Protein in Patients with Erosive and Non-erosive Rheumatoid Arthritis
title_fullStr The Diagnostic Utility of Anti-cyclic Citrullinated Peptide Antibodies, Matrix Metalloproteinase-3, Rheumatoid Factor, Erythrocyte Sedimentation Rate, and C-reactive Protein in Patients with Erosive and Non-erosive Rheumatoid Arthritis
title_full_unstemmed The Diagnostic Utility of Anti-cyclic Citrullinated Peptide Antibodies, Matrix Metalloproteinase-3, Rheumatoid Factor, Erythrocyte Sedimentation Rate, and C-reactive Protein in Patients with Erosive and Non-erosive Rheumatoid Arthritis
title_short The Diagnostic Utility of Anti-cyclic Citrullinated Peptide Antibodies, Matrix Metalloproteinase-3, Rheumatoid Factor, Erythrocyte Sedimentation Rate, and C-reactive Protein in Patients with Erosive and Non-erosive Rheumatoid Arthritis
title_sort diagnostic utility of anti-cyclic citrullinated peptide antibodies, matrix metalloproteinase-3, rheumatoid factor, erythrocyte sedimentation rate, and c-reactive protein in patients with erosive and non-erosive rheumatoid arthritis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2275423/
https://www.ncbi.nlm.nih.gov/pubmed/16295525
http://dx.doi.org/10.1080/17402520500233510
work_keys_str_mv AT shovmano thediagnosticutilityofanticycliccitrullinatedpeptideantibodiesmatrixmetalloproteinase3rheumatoidfactorerythrocytesedimentationrateandcreactiveproteininpatientswitherosiveandnonerosiverheumatoidarthritis
AT gilburdb thediagnosticutilityofanticycliccitrullinatedpeptideantibodiesmatrixmetalloproteinase3rheumatoidfactorerythrocytesedimentationrateandcreactiveproteininpatientswitherosiveandnonerosiverheumatoidarthritis
AT zandmangoddardg thediagnosticutilityofanticycliccitrullinatedpeptideantibodiesmatrixmetalloproteinase3rheumatoidfactorerythrocytesedimentationrateandcreactiveproteininpatientswitherosiveandnonerosiverheumatoidarthritis
AT sherery thediagnosticutilityofanticycliccitrullinatedpeptideantibodiesmatrixmetalloproteinase3rheumatoidfactorerythrocytesedimentationrateandcreactiveproteininpatientswitherosiveandnonerosiverheumatoidarthritis
AT orbachh thediagnosticutilityofanticycliccitrullinatedpeptideantibodiesmatrixmetalloproteinase3rheumatoidfactorerythrocytesedimentationrateandcreactiveproteininpatientswitherosiveandnonerosiverheumatoidarthritis
AT gerlir thediagnosticutilityofanticycliccitrullinatedpeptideantibodiesmatrixmetalloproteinase3rheumatoidfactorerythrocytesedimentationrateandcreactiveproteininpatientswitherosiveandnonerosiverheumatoidarthritis
AT shoenfeldy thediagnosticutilityofanticycliccitrullinatedpeptideantibodiesmatrixmetalloproteinase3rheumatoidfactorerythrocytesedimentationrateandcreactiveproteininpatientswitherosiveandnonerosiverheumatoidarthritis
AT shovmano diagnosticutilityofanticycliccitrullinatedpeptideantibodiesmatrixmetalloproteinase3rheumatoidfactorerythrocytesedimentationrateandcreactiveproteininpatientswitherosiveandnonerosiverheumatoidarthritis
AT gilburdb diagnosticutilityofanticycliccitrullinatedpeptideantibodiesmatrixmetalloproteinase3rheumatoidfactorerythrocytesedimentationrateandcreactiveproteininpatientswitherosiveandnonerosiverheumatoidarthritis
AT zandmangoddardg diagnosticutilityofanticycliccitrullinatedpeptideantibodiesmatrixmetalloproteinase3rheumatoidfactorerythrocytesedimentationrateandcreactiveproteininpatientswitherosiveandnonerosiverheumatoidarthritis
AT sherery diagnosticutilityofanticycliccitrullinatedpeptideantibodiesmatrixmetalloproteinase3rheumatoidfactorerythrocytesedimentationrateandcreactiveproteininpatientswitherosiveandnonerosiverheumatoidarthritis
AT orbachh diagnosticutilityofanticycliccitrullinatedpeptideantibodiesmatrixmetalloproteinase3rheumatoidfactorerythrocytesedimentationrateandcreactiveproteininpatientswitherosiveandnonerosiverheumatoidarthritis
AT gerlir diagnosticutilityofanticycliccitrullinatedpeptideantibodiesmatrixmetalloproteinase3rheumatoidfactorerythrocytesedimentationrateandcreactiveproteininpatientswitherosiveandnonerosiverheumatoidarthritis
AT shoenfeldy diagnosticutilityofanticycliccitrullinatedpeptideantibodiesmatrixmetalloproteinase3rheumatoidfactorerythrocytesedimentationrateandcreactiveproteininpatientswitherosiveandnonerosiverheumatoidarthritis